Flutamide NEW

Flutamide is a non-steroidal androgen antagonist belonging to the acylaniline group and is a first-line treatment for prostate cancer. It was first designed and synthesized by Schering-Plough Company in the United States, and was first marketed in the United States in 1989 as a treatment for prostate cancer. Because flutamide itself does not have any hormonal activity, the treatment of prostate disease effect is good, and has no effect on cardiovascular, and can maintain the patient's sexual function, at present in Europe and the United States has gradually become a common drug for the treatment of prostate cancer and prostate hyperplasia, but also can be used for androgen-related non-prostate diseases, there have been a large number of international studies. Moreover, flutamide has a low incidence of adverse reactions and can be well tolerated by patients when taken orally at low doses for multiple times, so it is widely used.

Pharmacological action

This product competes with androgens for androgen receptors in tumor sites, blocks uptake of androgens by cells, and inhibits the binding of androgens to target organs. After binding with androgen receptor, the product forms a receptor complex, enters the nucleus, and binds to nuclear protein, thus inhibiting the growth of tumor cells.

Adverse reaction

1 Male breast feminization, breast tenderness, sometimes accompanied by galactorrhea, can disappear if the dose is reduced or discontinued. 

2  A small number of patients may have diarrhea, nausea, vomiting, increased appetite, insomnia and fatigue. 

3 Rare decreased libido, transient liver dysfunction, and decreased sperm count. 

4 The potential cardiovascular effect of this product is less than diethylstilbestrol. 

5 Fetal contact can cause pseudohermaphroditism.